Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.

Paul J BröckelmannHorst MüllerTeresa GuhlKarolin BehringerMichael FuchsAlden A MocciaAndreas RankMartin SoeklerTom VielerThomas PabstChristian BauesBastian von TresckowPeter Borchmann Andreas Engert

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

After contemporary treatment of ES-HL, relapse mostly occurred > 12 months after first diagnosis. Polychemotherapy regimens such as BEACOPP are frequently administered and may constitute a reasonable treatment option for selected patients with relapse after ES-HL.

Keyphrases

early stage
hodgkin lymphoma
high dose
free survival
squamous cell carcinoma
radiation therapy
combination therapy
lymph node
sentinel lymph node
neoadjuvant chemotherapy